Time to halt perioperative chemotherapy for resectable colorectal liver metastasis?
Open Access
- 7 December 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 109 (3) , 242-243
Abstract
Colorectal liver metastasis (CRLM) is a treatable condition, with the prospect of cure in some patients in whom surgery and multimodal therapy is possible 1–3. Historical boundaries to liver resection (such as number, size, and location of CRLMs) have been replaced by poor cancer biology as the principal prognostic factor 4–7. Before liver resection, surgeons now assess what will stay (future liver remnant), rather than contemplating what will go (tumour burden), to determine surgical operability or need for preoperative modifications (for example, portal vein embolization or associating liver partition and portal vein ligation for staged hepatectomy) to increase resectability and prevent liver failure 3. Further technical advances are being introduced, such as simultaneous portal vein and liver vein embolization (liver vein deprivation) 8, and are now being assessed in ongoing prospective randomized trials. Systemic cytotoxic therapy (such as oxaliplatin or irinotecan), biological agents (bevacizumab or cetuximab), and immune checkpoint inhibitors have expanded systemic treatment options such that tumours are deemed suitable for resection 9. Unfortunately, the vast majority (70–80 per cent) experience recurrence after hepatectomy, most often in the liver (regrowth of persistent CRLMs) 10. Repeat liver resection with or without ablation techniques 2, hepatic artery infusion 11, and selective internal radiation therapy 12 or drug delivery are all possible for disease control. There are reports of improved progression-free survival but there may be no gain in overall survival, so the selection of patients is key to limiting what could be non-effective or even futile interventions.Keywords
This publication has 20 references indexed in Scilit:
- Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trialBritish Journal of Surgery, 2019
- Meta-analysis of the association between primary tumour location and prognosis after surgical resection of colorectal liver metastasesBritish Journal of Surgery, 2019
- Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastasesBritish Journal of Surgery, 2018
- Biomarkers in colorectal liver metastasesBritish Journal of Surgery, 2018
- Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastasesBritish Journal of Surgery, 2017
- Factors influencing recurrence following initial hepatectomy for colorectal liver metastasesBritish Journal of Surgery, 2016
- Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastasesBritish Journal of Surgery, 2015
- Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastasesBritish Journal of Surgery, 2015
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trialThe Lancet Oncology, 2014
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008